scholarly journals Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer

2014 ◽  
Vol 13 (9) ◽  
pp. 2203-2214 ◽  
Author(s):  
Josephine Kam Tai Dermawan ◽  
Katerina Gurova ◽  
John Pink ◽  
Afshin Dowlati ◽  
Sarmishtha De ◽  
...  
2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 7522-7522
Author(s):  
Takashi Eguchi ◽  
Kadota Kyuichi ◽  
Brent Evans ◽  
Camelia S. Sima ◽  
Thaylon Davis ◽  
...  

Cells ◽  
2019 ◽  
Vol 8 (4) ◽  
pp. 297 ◽  
Author(s):  
Bin Hu ◽  
Tanggang Deng ◽  
Hongchang Ma ◽  
Yan Liu ◽  
Peifu Feng ◽  
...  

The deubiquitinase DUB3 is frequently overexpressed in non-small cell lung cancer (NSCLC) and contributes to its malignant phenotype. However, the underlying molecular mechanism of DUB3 in NSCLC is largely unknown. In this study, we report that DUB3 regulates cell cycle progression by deubiquitinating cyclin A that links to proliferation of NSCLC cells. We found that knockdown of DUB3 decreases cyclin A levels, whereas overexpression of DUB3 strongly increases cyclin A levels. Mechanistically, DUB3 interacts with cyclin A, which removes the polyubiquitin chains conjugated onto cyclin A and stabilizes the cyclin A protein. Furthermore, we demonstrate that DUB3 regulates cell cycle progression by stabilizing cyclin A, because ablation of DUB3 arrests cell cycle from G0/G1 to S phase and the resulting effect can be rescued by introducing cyclin A into NSCLC cells. Functionally, we found that the effect of DUB3 on cyclin A mediates proliferation of NSCLC cells. Moreover, a significant correlation between DUB3 abundance and cyclin A expression levels were also found in NSCLC samples. Taken together, these results reveal that DUB3 functions as a novel cyclin A regulator through maintaining cyclin A stability, and that the DUB3-cyclin A signaling axis plays a critical role in cell cycle progression for proliferation of NSCLC.


Sign in / Sign up

Export Citation Format

Share Document